Form 4: Ultragenyx Pharmaceutical Inc. Executive Huang Dennis Karl Reports Stock Transactions

Officer Dennis Karl Huang reports acquisition and disposal of Ultragenyx Pharmaceutical Inc. stock and stock options.

Summary

• On March 1, 2025, Dennis Karl Huang, an officer of Ultragenyx Pharmaceutical Inc., acquired 14,494 shares of common stock through restricted stock units (RSUs) and 18,443 shares through the conversion of performance stock units.
• Also on March 1, 2025, Huang acquired 26,074 stock options with an exercise price of $42.92, exercisable over a ten-year period.
• On March 3, 2025, Huang disposed of 1,348 shares of common stock at $42.92 to cover tax withholdings related to the vesting of RSUs.
• Following these transactions, Huang directly owns 114,591 shares of Ultragenyx common stock and 26,074 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transactions are part of standard executive compensation and tax obligations. The acquisition of shares and options is a slightly positive signal.

Positives

• The acquisition of stock options and shares through RSUs and performance stock units conversion indicates confidence in the company's future performance by the officer.

Negatives

• The disposal of 1,348 shares to cover tax withholdings, while a normal occurrence, slightly reduces the officer's stake in the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company executives and their potential impact on the stock's performance.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.

Key Dates